Success Metrics

Clinical Success Rate
91.5%

Based on 43 completed trials

Completion Rate
91%(43/47)
Active Trials
4(7%)
Results Posted
93%(40 trials)
Terminated
4(7%)

Phase Distribution

Ph phase_4
6
11%
Ph phase_1
4
7%
Ph phase_3
34
62%
Ph phase_2
8
15%

Phase Distribution

4

Early Stage

8

Mid Stage

40

Late Stage

Phase Distribution52 total trials
Phase 1Safety & dosage
4(7.7%)
Phase 2Efficacy & side effects
8(15.4%)
Phase 3Large-scale testing
34(65.4%)
Phase 4Post-market surveillance
6(11.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.0%

43 of 50 finished

Non-Completion Rate

14.0%

7 ended early

Currently Active

4

trials recruiting

Total Trials

55

all time

Status Distribution
Active(4)
Completed(43)
Terminated(7)
Other(1)

Detailed Status

Completed43
Recruiting4
Terminated4
Withdrawn3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
55
Active
4
Success Rate
91.5%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (7.7%)
Phase 28 (15.4%)
Phase 334 (65.4%)
Phase 46 (11.5%)

Trials by Status

recruiting47%
terminated47%
unknown12%
withdrawn35%
completed4378%

Recent Activity

Clinical Trials (55)

Showing 20 of 55 trialsScroll for more
NCT04066192Phase 2

Brexpiprazole in Alcohol Use Disorder

Recruiting
NCT05169268

Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia

Completed
NCT05017311Phase 4

Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)

Recruiting
NCT03238326Phase 3

Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

Completed
NCT04174365Phase 3

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder

Completed
NCT05962216

Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders

Recruiting
NCT04124614Phase 3

Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD

Completed
NCT04174170Phase 3

Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder

Completed
NCT03526354Phase 4

Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder

Completed
NCT03874494Phase 3

Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia

Completed
NCT03620981Phase 2

Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Completed
NCT03557931Phase 2

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

Completed
NCT04186403Phase 2

Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)

Completed
NCT03724942Phase 3

Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Completed
NCT03697603Phase 2

A Study of Brexpiprazole in Patients With Major Depressive Disorder

Completed
NCT04569448Phase 3

Brexpiprazole Treatment for Bipolar I Depression

Recruiting
NCT04100096Phase 2

A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder

Completed
NCT04258839Phase 3

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148

Completed
NCT03737474Phase 3

A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder

Completed
NCT04830215Phase 4

Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder

Completed

Drug Details

Intervention Type
DRUG
Total Trials
55